New Two-Drug attack on Tough-to-Treat colon cancer
NCT ID NCT04599140
Summary
This study is testing a new two-drug combination for people with advanced colorectal cancer that has spread and is no longer responding to standard chemotherapy. The trial combines an experimental pill called SX-682, which aims to block tumor growth, with an existing immunotherapy drug (nivolumab) that helps the immune system fight cancer. The main goals are to find the safest dose and see if this combination can shrink tumors in patients who have very few treatment options left.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III RECTAL CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.